Early Response of Specific IgE can Predict Satisfaction with Sublingual Immunotherapy

Jin Youp Kim, Chae Seo Rhee, Sue Jean Mun, Seong H. Cho, Richard F. Lockey, Doo Hee Han

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Objective: To investigate predictive parameters at baseline and during the early response to sublingual immunotherapy (SLIT) for house dust mites in allergic rhinitis patients. Study Design: Retrospective cohort study. Methods: Patients were treated with SLIT for at least 3 years and serological tests performed at baseline and at 1-year follow-up to investigate predictive parameters. Satisfaction with SLIT, 4 nasal symptoms, and quality of life were evaluated before and after 3 years of SLIT. Sixty-one patients were enrolled and divided into two groups depending on their satisfaction after 3 years of SLIT: 43 were satisfied (70.5%) and 18 were not (29.5%). Results: Immunological parameters at baseline did not differ significantly between the satisfactory and unsatisfactory groups. However, changes in both Dermatophagoides pteronyssinus (Dp)– and D. farinae (Df)–specific IgEs were significantly higher in the unsatisfactory group than in the satisfactory group during the early response to SLIT (P =.006 and P =.045, respectively). Conclusion: The changes in both Dp- and Df-specific IgE levels during early response may be indicators for favorable long-term treatment outcomes with SLIT. These results suggest that clinicians could measure these immunological parameters 1 year after Dp and Df SLIT to indicate potential responders versus nonresponders. Level of Evidence: 2b Laryngoscope, 131:467–472, 2021.

Original languageEnglish
Pages (from-to)467-472
Number of pages6
JournalLaryngoscope
Volume131
Issue number3
DOIs
StatePublished - Mar 2021

Keywords

  • Allergic rhinitis
  • biomarkers
  • house dust mites
  • sublingual immunotherapy

Fingerprint

Dive into the research topics of 'Early Response of Specific IgE can Predict Satisfaction with Sublingual Immunotherapy'. Together they form a unique fingerprint.

Cite this